GMED moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 35 of 43 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on GMED as a result. In 59 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for GMED just turned positive on September 25, 2026. Looking at past instances where GMED's MACD turned positive, the stock continued to rise in 36 of 50 cases over the following month. The odds of a continued upward trend are 72%.
Following a +2.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMED advanced for three days, in 198 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.
GMED broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GMED entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. GMED’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.215) is normal, around the industry mean (2.923). P/E Ratio (19.819) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (1.493) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (3.275) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMED’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
On October 20, 2026, the Stochastic Oscillator for WRBY moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 55 instances where the indicator left the oversold zone. In 46 of the 55 cases the stock moved higher in the following days. This puts the odds of a move higher at over 84%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on WRBY as a result. In 63 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
WRBY moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where WRBY advanced for three days, in 226 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
WRBY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Moving Average Convergence Divergence Histogram (MACD) for WRBY turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 39 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
The 10-day moving average for WRBY crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WRBY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for WRBY entered a downward trend on September 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. WRBY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.082) is normal, around the industry mean (4.952). WRBY's P/E Ratio (427.167) is considerably higher than the industry average of (36.644). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (3.231) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WRBY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
GMED | ||
|---|---|---|
OUTLOOK RATING 1..100 | 85 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 65 | |
PRICE GROWTH RATING 1..100 | 46 | |
P/E GROWTH RATING 1..100 | 61 | |
SEASONALITY SCORE 1..100 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| GMED | WRBY | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 84% |
| Momentum ODDS (%) | 2 days ago 68% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 72% | 2 days ago 76% |
| TrendWeek ODDS (%) | 2 days ago 65% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 61% | 2 days ago 82% |
| Advances ODDS (%) | 10 days ago 64% | 2 days ago 82% |
| Declines ODDS (%) | 4 days ago 58% | 7 days ago 78% |
| BollingerBands ODDS (%) | 2 days ago 62% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 61% | 2 days ago 74% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GMED’s FA Score shows that 0 FA rating(s) are green while WRBY’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GMED’s TA Score shows that 4 TA indicator(s) are bullish while WRBY’s TA Score has 5 bullish TA indicator(s).
GMED (@Medical/Nursing Services) experienced а +3.11% price change this week, while WRBY (@Pharmaceuticals: Other) price change was +2.85% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.74%. For the same industry, the average monthly price growth was -3.62%, and the average quarterly price growth was +9.09%.
GMED is expected to report earnings on Nov 05, 2026.
WRBY is expected to report earnings on Nov 05, 2026.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+0.74% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
A.I.dvisor indicates that over the last year, GMED has been loosely correlated with TMCI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GMED jumps, then TMCI could also see price increases.
| Ticker / NAME | Correlation To GMED | 1D Price Change % | ||
|---|---|---|---|---|
| GMED | 100% | -0.35% | ||
| TMCI - GMED | 46% Loosely correlated | +1.72% | ||
| TNDM - GMED | 46% Loosely correlated | -1.03% | ||
| SYK - GMED | 44% Loosely correlated | -2.23% | ||
| MDT - GMED | 44% Loosely correlated | -1.69% | ||
| STE - GMED | 44% Loosely correlated | -1.64% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TDV | 102.71 | 0.98 | +0.97% |
| ProShares S&P Technology Dividend Aristocrats ETF (TDV) | |||
| VTI | 379.15 | 2.06 | +0.55% |
| Vanguard Morningstar Total Stock Market ETF (VTI) | |||
| CDEI | 94.96 | 0.48 | +0.51% |
| Calvert US Large-Cap Diversity, Equity and Inclusion Index ETF (CDEI) | |||
| EVSM | 49.61 | N/A | N/A |
| Eaton Vance Short Duration Municipal Income ETF (EVSM) | |||
| BBIB | 94.48 | -0.03 | -0.03% |
| JPMorgan BetaBuilders U.S. Treasury Bond 3-10 Year ETF (BBIB) | |||